Medpace Holdings reported a strong Q2 2026 performance that beat Street expectations, fueling a broad rally among CROs. The company raised its full-year 2026 GAAP earnings guidance and disclosed favorable quarterly results, sending MEDP up more than 15% intraday. Analysts lifted Medpace’s 12-month price target to about $490, with a range from $400 to $586, while keeping a consensus Hold rating that includes Buys, Holds and Sells. The broader CRO sector benefited in tandem from Medpace’s results and sentiment improved across peers. Market commentary included a caution from Seeking Alpha about AI-generated coverage, alongside mixed broker notes (e.g., Mizuho Outperform, Baird Neutral). Benzinga’s alerts summarized ongoing coverage and price-target movements across related reports.